1. Overview
The International Asthma Conference at Nemacolin 20th Annual Meeting provides a comprehensive update on the latest clinical and scientific advancements in asthma management. The program covers a broad spectrum of topics, including early-life determinants of asthma, the integration of biomarkers and molecular phenotyping, the safety and efficacy of biologic therapies, and strategies for achieving disease remission in both pediatric and adult populations.
Course Date: November 14–16, 2025
2. Learning Objectives
Evaluate the role of early-life viral infections, epigenetics, and social determinants in the etiology and long-term trajectory of childhood asthma.
Apply advanced clinical and molecular phenotyping and endotyping to personalize asthma treatment and advance towards disease remission.
Assess the safety considerations, clinical applications, and controversies surrounding the use of biologic therapies and rescue medications in asthma and COPD exacerbations.
Navigate current legal and policy barriers related to the integration of AI in respiratory medicine.
Understand the evolving safety profiles of inhaled corticosteroids and long-acting beta-agonists, and reevaluate the role of oral corticosteroids in the modern biologics era.
3. Target Audience
Best for pulmonologists, allergists, and immunologists who want updates on asthma endotyping, biologic therapies, and disease prevention strategies.
4. Topics
01 AI in Medicine – Navigating Current Legal and Policy Barriers
02 Atopic Dermatitis – Navigating First-Line and Emerging Management Strategies
03 Asthma Remission—Current Evidence and Clinical Implications
04 Asthma Remission – Strategies and Barriers in Achieving Disease Control
05 Roundtable Discussion Q&A – The Beginning and Ending of Asthma
06 Update on Gene Therapy for Lung Disease
07 Role of Empathy in Improving Patient–Provider Relationships
08 Safety Considerations for Biologic Therapies – What Should Clinicians Watch For
09 Asthma Trajectories From Childhood to Adulthood – Dunedin Cohort Findings
10 Asthma and Allergy in Childhood – Key Findings from the Manchester Asthma and Allergy Study
11 CHILD Cohort – Longitudinal Discovery in Asthma Prevention Strategies
12 Childhood Asthma Etiology – ECHO Cohort and CADRE Collaboration Insights
13 Viruses, Asthma, and Maternal Vaccines – Changing the Trajectory of Childhood Disease
14 Asthma Exacerbation in Children – Mechanisms of Rhinovirus-Triggered Events
15 Roundtable Discussion Q&A – Viruses and Asthma
16 A Biologic Should Be Administered as a Rescue Medication for Acute Eosinophilic Asthma and COPD Exacerbations – PRO
17 A Biologic Should Be Administered as a Rescue Medication for Acute Eosinophilic Asthma and COPD Exacerbations – CON
18 Roundtable Discussion Q&A – Biologics and Asthma
19 Treatable Traits in Asthma – Clinical Approach to Laryngeal Involvement
20 Asthma Phenotyping – Clinical Characteristics to Molecular Approaches
21 Asthma in Children – Advances in Clinical and Molecular Phenotyping
22 Asthma Biomarkers – Applications and Limitations in Clinical Management
23 Asthma Endotyping – Advancing Remission and Curative Strategies
24 Roundtable Discussion Q&A – Asthma Heterogeneity and the Evolution of Phenotyping
25 Origins of Asthma—Key Mechanisms in Disease Development and Progression
26 Asthma and Epigenetics – Environmental Factors Influencing Disease Pathogenesis
27 Asthma Exacerbations – Navigating the Role of Air Pollution in Disease Management
28 Asthma Outcomes and Social Determinants—What Clinicians Need to Know
29 Roundtable Discussion Q&A – Determinants of Asthma
30 Managing Pediatric Asthma – What Are the Safety Risks of Inhaled Corticosteroids
31 Orbital Manifestations of Cushing’s Syndrome – Diagnostic and Management Strategies
32 Asthma in the Biologics Era – Should Oral Corticosteroid Therapy be Relegated to History
33 Long-Acting Beta-Agonists – How Has Safety Understanding Changed Over Time




Reviews
There are no reviews yet.